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1% at (I  26). The application of chronological series
indicates that this decrease is significantly correlated to
the effects of the intervention (p  0.02). In addition, the
costs of ATP decreased from $40 to $24. 
CONCLUSIONS: 1) An important reduction of TIg pre-
scribing was obtained after the introduction of new
guidelines in our emergency department and is main-
tained 3 years later. 2) Rapid techniques are needed to
identify extemporaneously patients who require TIg.
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Hospital-acquired pneumonia (HAP) is associated with a
high mortality rate and a substantial economic burden.
Many clinical and economic studies do not differentiate
between HAP in the intensive care unit (ICU) versus on
the ward, even though they are associated with different
pathogens, treatment approaches, mortality and costs.
For nosocomial infections, the effectiveness of therapy is
dependent on the pathogenic organism and susceptibility
to prescribed antibiotics, factors that are specific to each
individual institution. 
OBJECTIVES: To develop decision analytic models for
current and anticipated antimicrobial regimens for the
initial treatment of ICU and non-ICU HAP, that incorpo-
rate site-specific pathogen and susceptibility profiles,
from the hospital perspective. 
METHODS: Two decision tree models were constructed,
one for ICU and the other for non-ICU HAP. The proba-
bilities for the decision analysis model were derived from
a meta-analysis of randomized, controlled clinical trials
and data from our hospital population. Antimicrobial
susceptibilities were obtained from the literature and lo-
cal data. The comparators included in the baseline analy-
sis were cefotaxime (CFX), ceftazidime (CTZ), ceftriax-
one (CTR), ciprofloxacin (CIP), imipenem (IMP), and
cefazolin  gentamicin (CG). Drug acquisition, phar-
macy, nursing, and hospitalization costs were included in
the analysis. Hospitalization costs were determined from
local case-costing data. Outcomes were measured as suc-
cess, failure, and death. 
RESULTS: For ICU HAP, CG dominated over IMP.
The incremental cost-effectiveness ratios for CTZ and
CIP were $66,087/success and $49,099/success, respec-
tively. For non-ICU HAP, CG dominated over CTR
and CFX. The incremental ratio for CTZ was $142,500/
success. Sensitivity analyses did not substantially alter the
results. 
CONCLUSIONS: Antimicrobial susceptibility is a clini-
cally important determinant of efficacy that should be in-
cluded in economic analyses of HAP and other infections.
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OBJECTIVES: The purpose was to identify motivating
factors and barriers on influenza vaccination. 
METHODS: An employer site conducting an annual influ-
enza vaccination program was selected for the study. Sub-
jects were recruited on-site to participate in the 5-month
study. The vaccinated group (VG) included subjects pre-
senting for vaccination over a 3-week vaccination schedule
in October 1998. During a subsequent 3-week period, vol-
unteers not receiving vaccination (NVG) were recruited
into the study. Health Belief surveys were administered at
the time of recruitment, which included questions specifi-
cally inquiring about health beliefs. The Health Belief
Model (HBM) was utilized to derive motivators, barriers,
threats, and expectations regarding influenza vaccination
and their influence on getting vaccinated. The influence of
the motivating factors and barriers were rated on a 4-point
rating scale (1  none, 4  a great deal). 
RESULTS: Preliminary results of motivating factors and
barriers on 1065 subjects (663 VG and 402 NVG) who
completed the surveys are presented. “Avoid influenza”
was reported most often as having a great deal of influ-
ence on getting vaccinated (86%, 524/606 subjects) fol-
lowed by “transmit influenza” (53%, 307/575 subjects).
Fear of injection and site pain (32%, 96/298 subjects)
and inconvenience (32%, 96/297 subjects) were reported
most often as having a great deal of influence as barriers
to vaccination. Additional multivariate analyses incorpo-
rating all aspects of HBM are ongoing. 
CONCLUSIONS: Perception of contracting and/or
transmitting influenza were primary motivators for seek-
ing vaccination. In the survey, there appear to be multiple
barriers to vaccination. Communication strategies and
noninvasive formulations of influenza vaccines may di-
minish these barriers and enhance vaccination rates.
PID16
ECONOMIC STUDY OF CEPHALOSPORINS IN 
THE TREATMENT OF MODERATE LOWER 
RESPIRATORY TRACT INFECTION
Zhigao HE, Chen J
Department of Hospital Management, Shanghai Medical 
University, Shanghai, China
The amount of antibiotics currently used in the hospital
has reached 35% of total drug consumption. The exten-
sive usage of antibiotics has not only brought drug resis-
tance, but also increased the economic burden of pa-
tients. Controlling the abuse of antibiotics and how to
